Rare Disease Delays: The High Cost of Perfect Regulation
The Urgent Need for FDA Flexibility in Rare Disease Treatment Washington D.C. – A growing chorus of patient advocates and medical experts are calling on the Food and Drug Administration (FDA) to more readily embrace flexible regulatory pathways for therapies targeting rare diseases. With existing frameworks already granting the agency discretion in evaluating these treatments, … Read more